TickerFacts.

Whitehawk Therapeutics, Inc. (WHWK): EBITDA

Operating income plus depreciation and amortization for the same annual period and currency, computed by TickerFacts from the filed figures. Not the company's adjusted EBITDA; a year without both inputs is left out.

-$114.32M
Year ended 2025-12-31
2020-12-31: -$2.54M2021-12-31: -$111.11M2022-12-31: -$62.52M2023-12-31: -$71.76M2024-12-31: -$67.27M2025-12-31: -$114.32M-$114.32M
2020-12-31 EBITDA (USD) 2025-12-31
Period endedEBITDAChange YoYSource filing
2025-12-31-$114.32Mn/m2026-03-12, From 2025-01-01
2024-12-31-$67.27Mn/m2026-03-12, From 2024-01-01
2023-12-31-$71.76Mn/m2025-03-28, From 2023-01-01
2022-12-31-$62.52Mn/m2024-03-13, From 2022-01-01
2021-12-31-$111.11Mn/m2023-03-29, From 2021-01-01
2020-12-31-$2.54Mn/a2022-03-17, From 2020-01-01

EBITDA at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedEBITDAChange YoY
Whitehawk Therapeutics, Inc. (WHWK)2025-12-31-$114.32Mn/m
Ovid Therapeutics Inc. (OVID)2025-12-31-$42.17Mn/m
Immunome Inc. (IMNM)2025-12-31-$221.65Mn/m
Xenon Pharmaceuticals Inc. (XENE)2025-12-31-$370.53Mn/m
Adagene Inc. (ADAG)2025-12-31-$21.00Mn/m
Bolt Biotherapeutics, Inc. (BOLT)2025-12-31-$34.82Mn/m
Aclaris Therapeutics, Inc. (ACRS)2025-12-31-$75.92Mn/m
Roivant Sciences Ltd. (ROIV)2026-03-31-$511.72Mn/m
International Stem Cell Corp (ISCO)2025-12-31-$48.0Kn/m

Compare WHWK, OVID, IMNM, XENE side by side · Screen every company in Pharmaceutical Preparations ↗